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Introduction Asenapine is a second-generation antipsychotic approved in Europe for the treatment of
manic or mixed episodes.
Objective To describe the clinical features of Asenapine responders and non-responders.
Methods A naturalistic, observational study is ongoing in patients treated with Asenapine. We have already
recruited 37 manic patients with a lifetime diagnosis of Bipolar I (BDI) or Schizoaffective Disorder referring
to our Psychiatric Ward. Patients are assessed with the Young Mania Rating Scale (YMRS) at baseline
(T0), and after 1 (T1) and 4 weeks (T2) of treatment. According to YMRS scores, patients are classified as
responders and non-responders.
Results The preliminary results highlight a significant improvement of the YMRS score from T0 to T2 in
most patients. Asenapine seems particularly effective in patients with less severe manic symptoms, and
responders are more likely to have lower baseline YMRS score. No correlation has currently emerged
between responder status and diagnosis. Non-responders in our sample are females sharing some clinical
features: early onset BDI diagnosis, several previous treatments (antipsychotics, mood stabilizers), initial
cognitive impairment confirmed with the Mini Mental State Examination, Alzheimer Disease Assessment
Scale and neuroimaging.
Conclusions Elderly manic patients with neurological impairment and/or dementia may have poorer
therapeutic outcomes and poorer response to pharmacological treatment, which may prove effective in
reducing agitation but not mania ratings. Diagnosis (BDI or schizoaffective disorder) does not seem to have
a significant impact on Asenapine efficacy. The further recruitment and assessment of patients is expected
to support the results described above.
